Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler speaks to Proactive's Stephen Gunnion about the start of an investigator-sponsored Phase 2 clinical trial focused on treating Post COVID Syndrome (PCS) with its lead compound, vidofludimus calcium. This drug is currently in Phase 3 trials for multiple sclerosis and has shown potential as a broad-spectrum antiviral.
Muehler explained that the trial, initiated by a group of German investigators, aims to investigate the role of viral reactivation in fatigue symptoms associated with PCS. The study builds on Immunic’s earlier work during the COVID-19 pandemic, which hinted at the drug's ability to reduce fatigue in hospitalized patients. Muehler highlighted the potential connection between Epstein-Barr virus reactivation and fatigue, a key area of interest that may also have implications for multiple sclerosis treatment.
“We are hopeful that this trial will provide supportive data linking virus reactivation and fatigue,” said Muehler.